ReviewEuropean journal of heart failure2021
Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial.
Review in European journal of heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04069156 (Antiplatelet Removal and HemocompatIbility EventS With the HeartMate 3 Pump IDE Study), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antiplatelet Removal and HemocompatIbility EventS With the HeartMate 3 Pump IDE Study
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2024Pooled it
- Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial.JAMA cardiology · 2025Trial
- Hemocompatibility Outcomes After Aspirin Withdrawal in Long-Term HeartMate 3 Left Ventricular Assist Device Patients on Vitamin K Antagonists.Artificial organs · 2026Article
- Incidence and clinical implications of aortic root thrombosis in LVAD patients: A single-center experience.Turk gogus kalp damar cerrahisi dergisi · 2026Article
- From Normal to Zero Flow in 30 Seconds on HeartMate 3 LVAD: What Happened?JACC. Case reports · 2025Article
- Advancing antithrombotic therapies for left ventricular assist devices: challenges, innovations, and future perspectives.Future cardiology · 2025Article
- The Impact of Genetic Polymorphism on Complication Development in Heart Failure Patients.Journal of clinical medicine · 2024Article
- Assessment of Platelet Response to Aspirin Therapy and Hemocompatibility-Related Adverse Events in HeartMate 3 Left Ventricular Assist Device Recipients.Journal of clinical medicine · 2024Article
- Platelet reactivity is associated with pump thrombosis in patients with left ventricular assist devices.Research and practice in thrombosis and haemostasis · 2024Article
- Hemocompatibility and biophysical interface of left ventricular assist devices and total artificial hearts.Blood · 2024Review
- Vibro-Acoustic Platelet Activation: An Additive Mechanism of Prothrombosis with Applicability to Snoring and Obstructive Sleep Apnea.Bioengineering (Basel, Switzerland) · 2023Article
- Gastrointestinal bleeding on continuous-flow left ventricular assist device therapy.ESC heart failure · 2023Review
- Review
- Acquired blood platelet disorder in patients with end-stage heart failure after implantation of a continuous centrifugal-flow left ventricular assist device: A prospective cohort study.Research and practice in thrombosis and haemostasis · 2023Article
- Neurologic Complications in Patients With Left Ventricular Assist Devices.The Canadian journal of cardiology · 2023Review
- Left Ventricular Assist Devices: A Primer For the General Cardiologist.Journal of the American Heart Association · 2022Review
- Heart failure: an update from the last years and a look at the near future.ESC heart failure · 2022Review
- Antithrombotic therapy for durable left ventricular assist devices - current strategies and future directions.Indian journal of thoracic and cardiovascular surgery · 2022Review
- Post-Implant Phosphodiesterase-5 Inhibitors in Patients with Left Ventricular Assist Device: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2022Review
- Ventricular Assist Devices: Challenges of the One-device Era.Cardiac failure review · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsOver decades, left ventricular assist device (LVAD) technology has transitioned from less durable bulky pumps to smaller continuous-flow pumps which have substantially improved long-term outcomes and quality of life. Contemporary LVAD therapy is beleaguered by haemocompatibility-related adverse events including thrombosis, stroke and bleeding. A fully magnetically levitated pump, the HeartMate 3 (HM3, Abbott, USA) LVAD, has been shown to be superior to the older HeartMate II (HMII, Abbott, USA) pump by improving haemocompatibility. Experience with the HM3 LVAD suggests near elimination of de-novo pump thrombosis, a marked reduction in stroke rates, and only a modest decrease in bleeding complications. Since the advent of continuous-flow LVAD therapy, patients have been prescribed a combination of aspirin and anticoagulation therapy on the presumption that platelet activation and perturbations to the haemostatic axis determine their necessity. Observational studies in patients implanted with the HM3 LVAD who suffer bleeding have suggested a signal of reduced subsequent bleeding events with withdrawal of aspirin. The notion of whether antiplatelet therapy can be avoided in an effort to reduce bleeding complications has now been advanced.
methodsTo evaluate this hypothesis and its clinical benefits, the Antiplatelet Removal and Hemocompatibility Events with the HeartMate 3 Pump (ARIES HM3) has been introduced as the first-ever international prospective, randomized, double-blind and placebo-controlled, non-inferiority trial in a patient population implanted with a LVAD.
conclusionThis paper reviews the biological and clinical role of aspirin (100 mg) with LVADs and discusses the rationale and design of the ARIES HM3 trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.